Toward a World Free fromViruses
Novelgen is a biotech company focused on R&D of broad-spectrum antiviral treatments based on recombinant antibodies and biologics, developing therapies for viruses without vaccines.
Taking on viruses with no cure — changing the paradigm through innovative materials.
New Paradigm for the Treatment and Prevention of Viral Infectious Diseases
Novelgen is a biotech R&D company that holds innovative materials and fundamental technologies related to the diagnosis, prevention, and treatment of viruses. Focusing on next-generation bio-organic materials 'PATA-X' and broad-spectrum antiviral substances 'NVG308', it has established an international collaborative research system with various domestic and foreign research institutions, universities, and companies, working towards a world free from viral diseases.
Postbiotics
What is PATA-X?
Pata-X is a next-generation green biobased material derived from pyridine derivatives, immediately exerting its effects. It formulates only the effective components, excluding live bacteria, thus achieving functionality, safety, and material stability.
Strong antiviral · anti-inflammatory effects · intestinal health and immune regulation
It has been confirmed that the product shows more than 90% virus suppression against a variety of viruses including Norovirus, Herpes Simplex Virus (HSV), Influenza A, Porcine Epidemic Diarrhea Virus (PEDV), Neonatal Pig Diarrhea (NCD), Avian Influenza (AI), Feline Infectious Peritonitis (FIP), Feline Calicivirus (FCV), Feline Herpesvirus (FHV), and Canine Parvovirus (CPV).
Exemplary Functional Stability
It is suitable for concentration, sterilization, asepsis, and powdering processes as it does not degrade active components at high temperatures. It can be stored at room temperature for a long time and has strong resistance to oxygen, moisture, and light. It maintains its function even in pH changes within the stomach, making effective delivery inside the body possible.
Various applications
It can be applied to a wide range of industrial fields including innovative new drug development, health functional foods, medicfood, cosmetics, animal pharmaceuticals and feed additives.
New alternatives to antibiotic resistance problem
By co-administering PATA-X, the efficacy of treatment can be enhanced as a potential alternative to antibiotic misuse and resistance issues.
To meet new viruses, mutated viruses and viruses with no available treatment, Novelgen concentrates on developing innovative materials and core technologies. We are building a technology roadmap that begins with postbiotics and extends to broad-spectrum antiviral therapeutics, growing into a global antiviral platform.
NVG308, a broad-spectrum antiviral agent
ALL-IN-ONE APPROACH
What if there were a therapeutic that worked against every virus? Novelgen has developed NVG308, a broad-spectrum antiviral agent capable of preventing and treating a wide range of viral infections regardless of viral genotype.
Nucleic acid–hydrolysing mini-antibody
NVG308 is a nucleic acid hydrolyzing mini-antibody that shows therapeutic activity against a broad range of viruses, regardless of genetic mutation or resistance to existing treatments.
Responding to influenza & avian flu
We are developing therapeutics that can both prevent and treat influenza and avian influenza, which cause problems worldwide, and that respond rapidly to newly emerging viruses.
Potential beyond Tamiflu
Novelgen's innovative antibody has the potential to grow into a blockbuster exceeding the sales of existing neuraminidase inhibitors such as Tamiflu (USD 15.5 billion, approx. KRW 17.5 trillion). It can be applied in monotherapy, in combination therapy, and in the treatment of patients infected with resistant virus strains.
A global research collaboration network
To develop a new class of antiviral prophylactics and therapeutics, we have established international joint-research partnerships with leading universities and research institutes in Korea and abroad. We are pursuing new drug development for a range of viral diseases including Zika, MERS and hantavirus.
Frequently Asked Questions
Questions about the PATA-X ingredient, NVG308 technology and partnerships, gathered in one place.
Latest News & Blog
Partners to build a world free from viruses
Research institution collaboration
We are exploring joint research with universities and research institutes in Korea and abroad. Innovative research collaboration in the antiviral field is always welcome.
Technology licensing
We are open to licensing and co-development of our PATA-X and NVG308 technologies, and are seeking partners in pharmaceuticals, veterinary medicine and health functional foods.
Investment Inquiry
We are looking for investors to join the growth of Novelgen's innovative antiviral technology. IR materials and a business briefing are available on request.
Clinical & product development collaboration
We welcome pharmaceutical companies and medical institutions interested in taking part in NVG308 clinical trials or in co-developing products. Let us write a new chapter in treatment together.
Enquire about development collaboration →Ingredient purchasing enquiries
We welcome purchasing enquiries from companies looking to adopt the PATA-X postbiotic ingredient in health functional foods, feed additives and food processing.
Enquire about purchasing →